Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01799473 · ClinicalTrials.gov registry record
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
A clinical trial, sponsored by United Therapeutics.
- Completed
- Registry status
- 98
- Enrollment target
NCT01799473 is a clinical trial that has completed, run by United Therapeutics. The registered enrollment target is 98 participants.
The verdict
NCT01799473 has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01799473
The ClinicalTrials.gov registry entry for NCT01799473 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01799473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01799473 about?
NCT01799473 is a clinical study titled "Tyvaso Dosing and Titration Evaluation: TyTRATE Registry". This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call...
What is the current status of trial NCT01799473?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2013-01. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01799473?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.